A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Atezolizumab (Primary) ; Guadecitabine (Primary) ; Rasdegafusp-alfa (Primary) ; Poly ICLC
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Apr 2024 Planned End Date changed from 31 Mar 2024 to 31 Mar 2025.
- 02 Apr 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Mar 2025.
- 01 Apr 2023 Planned End Date changed from 31 Mar 2023 to 31 Mar 2024.